Comprehensive Evaluation of the Effects of Enalapril on Matrix Metalloproteinases Levels in Hypertension
- 21 October 2012
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 26 (6) , 511-519
Abstract
Angiotensin-converting enzyme inhibitors (ACEi) may downregulate matrix metalloproteinases (MMPs). We examined whether enalapril affects MMP-2, MMP-8, and MMP-9 levels and activity, and their endogenous inhibitors (tissue inhibitors of MMPs, TIMP-1 and TIMP-2) levels in hypertensive patients. Moreover, we assessed the effects of enalaprilat on MMP-9 and TIMP-1 secretion by human endothelial cells (HUVECs). Thirty-eight hypertensive patients received enalapril for 8 weeks and were compared with thirty-eight normotensive controls. Blood samples were collected at baseline and after treatment. Plasma ACE activity was determined by a fluorimetric assay. Plasma MMP-2, MMP-8, MMP-9, TIMP-1, and TIMP-2 were measured by ELISA and gelatin zymography. A fluorogenic peptide cleavage assay was used to measure MMP activity. HUVECs cells were stimulated by phorbol-12-myristate-13-acetate (PMA) and the effects of enalaprilat (10−10 to 10−6 M) on MMP-9 and TIMP-1 levels were determined. Enalapril decreased blood pressure and ACE activity in hypertensive patients (P < 0.05), but had no effects on plasma MMP-2, MMP-8, MMP-9, TIMP-1, and TIMP-2 levels, or MMP activity. Enalaprilat had no effects on PMA-induced increases in MMP-9 and TIMP-1 secretion by HUVECs or on MMP activity. We show consistent evidence, both in vivo and in vitro, that enalapril does not affect MMPs and TIMPs levels in hypertensive patients.Keywords
This publication has 39 references indexed in Scilit:
- Circulating matrix metalloproteinases and their inhibitors in hypertensionClinica Chimica Acta, 2012
- Consistent Alterations of Circulating Matrix Metalloproteinases Levels in Untreated Hypertensives and in Spontaneously Hypertensive Rats: A Relevant Pharmacological TargetBasic & Clinical Pharmacology & Toxicology, 2011
- Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patientsHypertension Research, 2010
- Matrix Metalloproteinase Inhibition Improves Cardiac Dysfunction and Remodeling in 2-Kidney, 1-Clip HypertensionJournal of Cardiac Failure, 2010
- Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase‐2 activity and expression in a model of renovascular hypertensionBritish Journal of Pharmacology, 2010
- Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodelingMatrix Biology, 2010
- Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatmentEuropean Journal of Internal Medicine, 2009
- Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9Journal of Molecular and Cellular Cardiology, 2007
- Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active siteBiochemical and Biophysical Research Communications, 2007
- Different Effect of Antihypertensive Drugs on Conduit Artery Endothelial FunctionHypertension, 2003